T2Sepsis Solution

The T2Sepsis SolutionTM is a unique approach that combines the best standard of care for the management of sepsis patients with T2 Biosystems’ products, including the T2Dx® Instrument and T2Candida® Panel, and the T2Bacteria® Panel, which is available for the research use only in the US and commercially available in Europe and other countries that accept the CE mark. 

Powered by T2 Magnetic Resonance (T2MR®) technology, the T2Sepsis Solution enables faster and more accurate testing for the detection of sepsis-causing pathogens than previously possible. The advantage of T2MR, based on results from the proven T2Candida Panel, is clear: highly accurate results with a sensitivity greater than 90% are available in just hours, not days.1

Proven to deliver better patient care and greater cost savings

Run on the T2Dx Instrument, the T2Candida Panel targets Candida, one of the deadliest sepsis-causing pathogens. In fact, it is known to have a staggering 40% mortality rate, and costs healthcare systems an average of $130,000 per patient.2,3 The T2Dx platform is currently available in approximately 130 hospitals in the United States and Europe.

  • Based on actual length-of-stay data, Henry Ford Hospital System in Michigan demonstrated that it was able to treat patients faster and more effectively with antifungal therapy, thereby projecting $2.3 million in total cost savings annually.4  

  • By implementing the T2Candida Panel, Lee Health System in Florida reduced length of stay (LOS) by an average of 7 days, while also decreasing the use of unnecessary antifungals, ultimately achieving net savings of about $200 per patient.5

  • Robert Wood Johnson University Hospital in New Jersey reported that negative T2Candida results led to cessation or no initiation of antifungal therapy in 67% of patients. In addition, preliminary results at their institution suggest that the T2Bacteria Panel has the potential to identify infections that may be missed by blood culture.6  

  • Riverside Hospital in California was able to place 100% of patients who tested positive for sepsis-causing Candida on appropriate treatment within nine hours. None of these patients with an infection had even been considered for necessary antifungals prior to the T2Candida test.7

  • Huntsville Hospital in Alabama detected 56% more positive Candida patients than with standard blood culture. And for its negative patients, the hospital saved ~$500 per patient in medication costs due to the reduction in duration of drug therapy.8

Expanding the T2Sepsis Solution to include the T2Bacteria Panel

The T2Sepsis Solution is expanding to include the T2Bacteria Panel, which is anticipated to be commercially available in the US in early 2018. T2Bacteria is CE marked and commercially available in the EU and available for Research Use Only (RUO) in the US.

Thanks to the aggressive efforts of clinicians and hospitals, about 60% of symptomatic patients today are on the appropriate antimicrobial therapy within the critical 12-hour window. But the limitations of current diagnostic tests leave about 40% of patients waiting too long for the right diagnosis and treatment.

The combined results from the T2Candida and T2Bacteria Panels—along with empiric antimicrobial therapy—will enable up to 95% of patients to receive effective therapy within those first critical 6 hours.9,10

 

Sepsis – a serious public health crisis

Sepsis is one of the greatest challenges facing hospitals today. Sepsis contributes to nearly one in two hospital deaths.11 In fact, it is the most expensive hospital-treated condition in the U.S., representing $27B in U.S. healthcare costs,12,13 and it is the most frequent cause of hospital readmissions.14 

Treating patients at risk of sepsis effectively—a major unmet need in healthcare

There are over 100 drugs that combat sepsis-causing pathogens; the greatest challenge for clinicians is to quickly identify the sepsis-causing pathogen and administer targeted treatment. The underlying problem? All current diagnostics rely on blood culture. However, culturing blood takes up to 5 days and misses up to half of infections.15 When nearly half of patients are missed in the critical first step, even the most accurate downstream blood-culture-reliant diagnostics cannot detect what blood culture missed.

No-blood-culture detection—the future of sepsis diagnostics is here today

Research has shown that the mortality rate for sepsis, if left unmanaged, rises by 8% every hour.16 Information to help clinicians target treatment in hours, not days, is the key to making a real difference in outcomes for patients with sepsis.

At T2, our mission is to save lives and improve healthcare. We believe that having the greatest impact on patients and their families requires a new approach that detects sepsis-causing pathogens directly from whole blood, without a blood culture.

……………………………………….

1. Mylonakis, E., Clancy, C. J., Ostrosky-Zeichner, L., Garey, K. W., Alangaden, G. J., Vazquez, J. A., … & Zervou, F. N. (2015). T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clinical Infectious Diseases, ciu959.
2. Parkins, M. D., et al. (2007). Journal of Antimicrobial Chemotherapy, 60(3), 613-618.
3. Gagne, J. J., Breitbart, R. E., Maio, V.,et. al. (2006). Costs associated with candidemia in a hospital setting. P and T, 31(10), 586.
4. Wilson, N.M., Kenney, R.M.,  Tibbetts, R.J., et. al.  T2 Magnetic Resonance Improves the Timely Management of Candidemia. Poster Presentation IDWeek 2016.
5. Estrada, S. J. Real World Value of T2Candida Lee Memorial Hospital. Slide Presentation ASM 2016.
6. Kirn, T.J. T2Candida Assay Implementation at Robert Wood Johnson University Hospital. Slide Presentation ASM Microbe 2017.
7. Patel F, Young E. Antifungal Prescribing During Initial Implementation of Candidemia Early Detection and Species Identification Testing with T2Candida Panel. Poster Presentation IDWeek 2016.
8. Kateon H et al. Utilization of T2Candida Panel for the rapid detection of Candida species in a large community hospital. Poster Presentation IDWeek 2016.
9. Buehler, S. S., Madison, B., Snyder, S. R., Derzon, J. H., Cornish, N. E., Saubolle, M. A., … & Wolk, D. M. (2016). Effectiveness of practices to increase timeliness of providing targeted therapy for inpatients with bloodstream infections: a laboratory medicine best practices systematic review and meta-analysis. Clinical microbiology reviews, 29(1), 59-103.
10. Kumar, A., Ellis, P., Arabi, Y., Roberts, D., Light, B., Parrillo, J. E., … & Peters, C. (2009). Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. CHEST Journal, 136(5), 1237-1248.
11. Liu, V., Escobar, G. J., Greene, J. D., Soule, J., Whippy, A., Angus, D. C., & Iwashyna, T. J. (2014). Hospital deaths in patients with sepsis from 2 independent cohorts. Jama, 312(1), 90-92.
12. Torio, C. M., Moore, B. J. (2016). Statistical Brief# 204. Healthcare Cost and Utilization Project (HCUP). May.
13. McDermott, K. W., Elixhauser, A., Sun, R. (2017). Statistical Brief# 225. Healthcare Cost and Utilization Project (HCUP). June.
14. Mayr, F. B., Talisa, V. B., Balakumar, V., Chang, C. C. H., Fine, M., & Yende, S. (2017). Proportion and cost of unplanned 30-day readmissions after sepsis compared with other medical conditions. Jama, 317(5), 530-531.
15. Clancy, C. J., & Nguyen, M. H. (2013). Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clinical infectious diseases, 56(9), 1284-1292.
16. Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., … & Gurka, D. (2006). Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical care medicine, 34(6), 1589-1596.